Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, G.
Right arrow Articles by Howe, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jin, G.
Right arrow Articles by Howe, P. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 272, Number 42, Issue of October 17, 1997 pp. 26620-26626
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

Regulation of Clusterin Gene Expression by Transforming Growth Factor beta *

(Received for publication, March 27, 1997, and in revised form, August 4, 1997)

Ge Jin and Philip H. Howe Dagger

From the Department of Cell Biology (NC-1), Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195 and the Department of Physiology and Biophysics, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Transforming growth factor beta  (TGFbeta ) induces the expression of a wide variety of genes in many cell types. Our previous studies have shown that TGFbeta stimulates both clusterin mRNA and protein levels, and induces its accumulation in the nucleus of CCL64 cells. To further investigate the molecular mechanism of clusterin mRNA induction by TGFbeta , we created a 1.3-kilobase rat clusterin promoter/luciferase reporter construct. We demonstrate that TGFbeta enhances luciferase activity 2.5-6-fold in transient transfection assays of epithelial, endothelial, and fibroblast cell lines. Deletional analysis reveals that an AP-1-binding site (5'-TGAGTCA) in the minimal promoter region is necessary for initiating transactivation by TGFbeta . A single T to G base mutation in the AP-1 site (5'-TGAGGCA) abolishes TGFbeta -induced clusterin promoter transactivation. In transcription factor decoy experiments, 23-mer oligonucleotides of wild type AP-1 reduce TGFbeta induction of clusterin mRNA levels and promoter transactivation, while an oligonucleotide containing the mutated AP-1 site has no effect. Two specific protein kinase C inhibitors, GF109203X and calphostin C, block TGFbeta -induced clusterin mRNA levels and promoter transactivation. Together these results indicate that TGFbeta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.


INTRODUCTION

The transforming growth factor-beta (TGFbeta )1 family of cytokines consists of multifunctional proteins which play important roles in regulating cell growth, development, and differentiation (1-6). A number of structural and metabolic proteins, such as fibronectin and its receptor, collagen, collagenase, plasminogen activator inhibitor type-1, and clusterin, have been shown to be regulated by TGFbeta . In addition, expression of some cellular oncogenes, such as c-jun, junB, and c-fos, and TGFbeta itself are also regulated by TGFbeta (2, 5, 7-11). TGFbeta regulates expression of its responsive genes through binding to specific membrane TGFbeta receptors, which possess Ser/Thr kinase activity, and triggering an unknown signaling cascade to modulate the interaction of transcription factors and their cognate cis-elements (2, 12-14). Recent studies have shown that Smad proteins, which are postulated to function as TGFbeta receptor-regulated transcription factors, may act as cellular mediators in TGFbeta signaling of mammalian cells and play a critical role in transmitting the TGFbeta signal to the nucleus (15, 16). Protein kinase C and other protein kinases have also been implicated in TGFbeta -mediated regulation of gene expression. These kinases may participate in recruitment of transcription factors, such as activator protein 1 (AP-1), to modulate TGFbeta responsive gene expression (6, 7, 15, 17-22). Many TGFbeta responsive genes, such as plasminogen activator inhibitor type-1, contain AP-1 consensus sequences in their regulatory region, and the sequence is required for TGFbeta regulation of genes in both growth-stimulated and growth-inhibited cell lines (7, 8, 23-26). Sp1 has been shown to participate in the regulation of human alpha 2(I)-collagen and p21/Waf1/Cip1 gene expression by TGFbeta (27, 28). Nuclear factor 1 also appears to be involved in expression of several genes regulated by TGFbeta (29). TGFbeta modulates interaction of theses transcription factors and their cognate elements in a coordinated manner to specifically regulate TGFbeta -responsive gene expression. However, the signaling pathway(s) through which TGFbeta modulates gene responses in mammalian cells remains largely unknown.

The clusterin protein was first discovered in ram rete testis fluid as an ~80-kDa heterodimeric glycoprotein that facilitated the aggregation of a variety of cells in culture (30). A number of homologues of clusterin have been identified in several species (31). Clusterin is present in almost all mammalian body fluids and can also be induced or constitutively expressed in almost all cell types (30, 31). The protein has been implicated in a variety of biological processes including lipid transport, inhibition of complement attack, sperm maturation, epithelial cell differentiation, and membrane remodeling during apoptosis and implantation (31-37). Analysis of the 5'-regulatory region of the clusterin gene has revealed TGFbeta inhibitory elements as well as AP-1, Sp1, and AP-2 regulatory elements in the quail, rat, and human clusterin genes (38-41). These elements are postulated to be responsible for the modulation of clusterin gene expression observed during cell differentiation, development, and embryogenesis (31, 35, 39-41). It has also been demonstrated that clusterin gene expression can be regulated by TGFbeta in a cell type-dependent manner (35, 42). For example, TGFbeta down-regulates clusterin mRNA levels in porcine smooth muscle cells (35), induces its gene expression in rat astrocytes in the presence of oligodendrocytes and microglia, while repressing its message in monotypic cultures of astrocytes (42). However, the mechanism(s) of regulation of clusterin gene expression by TGFbeta is unknown.

We have previously reported that TGFbeta induces expression of clusterin protein and rapidly stimulates clusterin mRNA levels in a mink lung epithelial cell line CCL64 cells (Mv1Lu). We have also demonstrated that TGFbeta selectively induces accumulation of clusterin protein in the nucleus (11, 43). To further dissect the mechanism of TGFbeta -mediated regulation of clusterin gene expression, we have analyzed the intracellular signaling pathway through which TGFbeta modulates gene expression. Our results demonstrate that TGFbeta regulates clusterin gene expression in epithelial, fibroblasts, and in a primary culture of bovine aortic endothelial cells, at least in part, at the transcriptional level. An AP-1 site in the rat clusterin 5'-promoter region is responsible for the regulation of clusterin gene expression by TGFbeta , and the effect of TGFbeta on clusterin gene expression requires the involvement of protein kinase C. 


MATERIALS AND METHODS

Cell Culture

Mink lung epithelial cells, HeLa cells, 3TP cells (derived from HT1080 (44)), and 10T1/2 cells were cultured in DMEM/F-12 medium containing 10% newborn calf serum (Atlanta Biological Inc.) at 37 °C with 5% CO2. The primary culture of bovine aortic endothelial cells (BAEC) was grown in DMEM/F-12 medium containing 10% fetal bovine serum (Sigma) at 37 °C with 5% CO2.

Northern Blot Analysis

Cells from confluent cultures were harvested and seeded at 3~5 × 106 cells per 100-mm plate. After attaining 50% confluence the plates were treated with TGFbeta (5 ng/ml) for different periods. For Northern blot analysis with serum-starved CCL64 cells, the serum medium was replaced with DMEM/F-12 medium containing 0.1% bovine serum albumin once the cells had reached 50~60% confluence. The cells were incubated at 37 °C for 24 h prior to TGFbeta stimulation. Total RNA was extracted by guanidine isothiocyanate according to Chomczynski and Sacchi (45), and separated (20 µg of RNA/well) in 1.2% formaldehyde gels. The RNA was transferred to NytranPlus nylon membrane (Schleicher & Schuell) by capillary blotting and hybridized with a random-labeled (Pharmacia) full-length human clusterin cDNA at 2-4 × 106 cpm/ml. The same blot was stripped with 55% formamide, 2 × SSC, 1% SDS for 60 min at 65 °C, and the membrane was re-probed with 32P-labeled human cyclophilin cDNA (1B15) to ensure equal loading of the RNA. The hybridization strength was analyzed by autoradiography (11).

DNA Subcloning and Deletions

pLLTRPM2+ plasmid (kindly provided by Dr. Martin Tenniswood) containing a rat clusterin 5'-regulatory region from +57 to -1297 was digested with SphI and HindIII and subcloned into pGL2-basic luciferase reporter vector (Promega) to form a pRAL plasmid for transient transfection, deletion, and mutagenesis experiments. Four deletions were obtained using restriction enzymes: pRAL-S/A starting from -218 to +57 was generated by digestion of pRAL with SacI and ApaI; pRAL-M/Nsi deletion contains promoter region from -729 to +57 produced by restriction enzymes MluI and NsiI. The others are internal deletions pRAL-N/A (-728 to -218 was deleted) and pRAL-E/E (-609 to -30 was deleted) generated by NsiI/ApaI and Eco47III, respectively. To make deletions around the AP-1 site, the following series of primers were synthesized according to the sequence of pRAL and used for polymerase chain reaction amplification and subcloning (see Fig. 2B): P1, 5'-GTTTGCAGCCAGCCAAAG-3'; P2, 5'-CCAGAGGAATTCATTATCAG-3'; P3, 5'-AGAATGCCGGGGAATGCACTAGGAG-3'; P4, 5'-CAGAAAGCTCCTAGTGCATTC-3'.


Fig. 2. Effect of TGFbeta on rat clusterin promoter transcriptional activity. A, effect of TGFbeta on rat clusterin promoter transcriptional activity in transient transfection experiments of CCL64 cells. 2 × 105 cells were transfected with 2 µg of promoter-reporter plasmid and 1 µg of SV40 beta -galactosidase DNA (Promega) as an internal control. Luciferase activity was measured as relative light units with a luminometer and normalized by beta -galactosidase activity of SV40 beta -galactosidase. Induction of promoter transactivation was calculated by comparing normalized luciferase activity of transfected cells treated with or without TGFbeta . The data represent duplicate experiments. B, construction of promoter-reporter plasmids for transient transfection analyses. The pRAL was constructed by subcloning a 1326-base pair 5'-regulatory region of rat clusterin gene into a luciferase reporter vector pGL-2 basic (Promega). A series of promoter deletions were made based on pRAL. Primers p1/p2 and p1/p3 were used to create AP-1 deletions, and p2/p4 was used to construct a minimal promoter containing the AP-1-binding site.
[View Larger Version of this Image (21K GIF file)]

Site-directed Mutagenesis

A single site-directed mutant in the AP-1-binding site of the promoter was created basically as described by Deng and Nickoloff (46). The mutagenic primer, 5'-CTGGCGTGAGGCACGCAGGTTTG-3', corresponds to -62 to -85 of the promoter region centered by a mutated AP-1-binding site (the underlined represents the base that was mutated). The selection primer, 5'-GCGACTGGTGAGGCCTCAACCGGCTTC-3', contains a single base mutation in a ScaI restriction site within the vector; therefore, the mutant will not be cleaved by ScaI. To create the mutation, the mutagenic and selection primers were phosphorylated with T4 kinase (Promega) and annealed to denatured plasmid pRAL to generate mutated first strand DNA by Klenow fragment. Then the DNA was cut by ScaI to digest wild type plasmid while the DNA hybrid remained intact. Competent BMH71-18 mutS cells (CLONTECH) were transformed by the DNA hybrid and incubated at 37 °C overnight to amplify mutated plasmid. After incubation, the plasmid was isolated and subjected to secondary ScaI digestion. The undigested, mutated plasmid was used to transform JM109 cells (Promega) and colonies were picked for plasmid preparation. The mutated plasmid was confirmed by sequencing and termed pT2G. The wild type rat clusterin 5'-promoter region contains an AP-1 consensus sequence as 5'-TGAGTCA-3', the mutated AP-1 site has the sequence 5'-TGAGGCA-3' at the same position in the promoter region.

Transient Transfection Assays

Transfection assays were carried out using liposomes prepared as described by Campbell (47). Briefly, 50 µl of lipid mixture containing 13.4 mM 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (Avanti Lipid Inc.) and 6.6 mM dimethyldiocatadecyl ammonium bromide (Sigma) in 100% ethanol were added to 1 ml of sterile water with vortexing. For transfection, cells were plated in 6-well plates at a density of 2 × 105 cells/well and incubated in DMEM/F-12 medium containing 10% newborn calf serum at 37 °C until 70-80% confluent. For transfection assay of CCL64 cells, 30 µl of liposome reagent (~3 µg of lipid) was added to 1 ml of serum-free medium, mixed with 2 µg of luciferase reporter plasmid and 1 µg of pSV-beta -galactosidase plasmid (Promega) as an internal control, and incubated at room temperature for 30 min to form a liposome-DNA complex. Prior to transfection, cells were washed twice with serum-free DMEM/F-12 medium, then 1 ml of liposome-DNA complex was added to the cells and incubated at 37 °C for 5 h before adding TGFbeta . For transfection assays with other cell lines, 20 µl of liposome reagent, 1 µg of reporter plasmid DNA, and 0.2 µg of pRL-CMV plasmid (Promega) as an internal control were used. All other procedures were the same as for transfections of CCL64 cells. After removing the transfection medium, serum or serum-free medium containing TGFbeta was added to the cells and incubated for 16 or 20 h at 37 °C prior to extraction of cellular lysates.

Decoy Experiments of Transcription Factors

Sense and antisense 23-mer oligonucleotides, containing either AP-1-binding site (AP-1) or its mutant (T2G) from the rat clusterin promoter region, were synthesized and annealed to form double-stranded DNA. The sequence of the 23-mer AP-1 oligonucleotide is 5'-CTGGCGTGAGTCACGCAGGTTTG-3' (the AP-1 consensus site is bold faced), and that of the T2G oligonucleotide is 5'-CTGGCGTGAGGCACGCAGGTTTG-3' (the T to G single site mutation is underlined). For decoy assays analyzed by Northern blot, 20 nmol of DNA was mixed with 30 µl of liposome reagent in 2 ml of serum-free medium, and incubated at room temperature for 30 min to form a liposome-DNA complex. Cells, 80% confluent, were washed with serum-free medium prior to the addition of the liposome-DNA complex. After incubation for 2 h, the cells were stimulated with 5 ng/ml TGFbeta for 10 h and subjected to RNA extraction and Northern blot analysis. To perform decoy experiments in transient transfection assays, 0.7 µg of oligonucleotide was added along with pRAL (100:1 molar ratio) into liposome reagent for transfection and luciferase activity.

Luciferase and Galactosidase Activity Assays

Following transient transfection and TGFbeta stimulation, cells were washed with phosphate-buffered saline two times and lysed at room temperature in 300 µl of lysis buffer (25 mM Tris phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM CDTA, 10% glycerol, 1% Triton X-100). The cell lysate was scraped into a microcentrifuge tube and centrifuged at high speed for 30 s at room temperature to remove cell debris. Cell lysates (10 µl) were mixed with 100 µl of luciferase substrate buffer (Promega) and luciferase activity was measured immediately (ML2250 Microtiter Plate Luminometer, Dynatech Laboratories). For lysates from cells transfected with pRL-CMV plasmid as an internal control construct, the reporter plasmid and control plasmid luciferase activities were measured with Promega's Dual-Luciferase Reporter Assay System according to manufacture's protocol. To measure galactosidase activity, 150 µl of 2 × beta -galactosidase buffer (0.2 M NaPO4, pH 7.3, 2 mM MgCl2, 0.1 M beta -mercaptoethanol, 1.33 mg/ml o-nitrophyenyl beta -D-glactopyranoside) was added to 150 µl of cell lysate. Following incubation at 37 °C overnight, 600 µl of H2O was added to beta -galactosidase reaction mixture and A420 was read with a spectrophotometer (UV160U, Shimadzu) to quantify beta -galactosidase activity. The promoter/reporter luciferase activity was normalized to beta -galactosidase activity or renilla luciferase activity of the Dual-Luciferase Reporter Assay System, respectively.


RESULTS

TGFbeta Induces Clusterin mRNA Synthesis

We have previously demonstrated that TGFbeta induces clusterin protein synthesis and accumulation of clusterin in the nucleus of CCL64 cells (11). However, the TGFbeta signaling pathway mediating this induction remains unknown. Therefore, we were interested in studying the regulation of clusterin gene expression by TGFbeta in an attempt to identify some of the signaling components involved. Northern blot analysis showed that TGFbeta induces clusterin mRNA as early as 30 min after TGFbeta treatment and continues about 24 h in rapidly growing, asynchronous CCL64 cells (Fig. 1, A and B). To determine whether the induction of clusterin RNA synthesis was a consequence of the growth-inhibitory effect of TGFbeta on the cells, CCL64 cells were serum starved in serum-free DMEM/F-12 medium for 24 h, prior to treatment with TGFbeta for different periods. As shown in Fig. 1C, TGFbeta also induces clusterin mRNA synthesis in serum-starved, quiescent cells, indicating that induction of clusterin mRNA level by TGFbeta is not a result of growth inhibition of the cells. The induction of clusterin mRNA by TGFbeta is not restricted to mink lung epithelial cells. The data presented in Fig. 1D demonstrates that TGFbeta can also induce clusterin gene expression in other cell types. In two fibroblasts cell lines, 10T1/2 and 3TP, two epithelial cell lines, CCL64 and HeLa, and in primary BAEC, TGFbeta induces clusterin mRNA levels following a 16-h treatment.


Fig. 1. Effect of TGFbeta on induction of clusterin mRNA levels. A, effect of TGFbeta on clusterin mRNA levels in rapidly growing CCL64 cells. CCL64 cells (60-70% confluent) growing in serum medium were treated with 5 ng/ml TGFbeta for 0.5-24 h, and total RNA was isolated and processed for Northern blot analyses. The hybridization bands on the autoradiographic films were quantitated by a densitometer and hybridization strength of clusterin was normalized with that of cyclophilin RNA. The data represent three independent experiments. B, representation of a Northern blot showing the induction of clusterin mRNA levels in CCL64 cells by TGFbeta . C, effect of TGFbeta on clusterin mRNA levels in serum-starved cells. Once CCL64 cells had reached 60% confluence, serum medium was replaced with serum-free medium. After a 24-h incubation, TGFbeta was added and the cells were incubated for different periods as indicated in the figure. D, effect of TGFbeta on clusterin mRNA levels in HeLa, 3TP, 10T1/2, and BAEC cells. The cells (60% confluent) were treated with 5 ng/ml TGFbeta for 16 h, then total RNA was extracted and subjected to Northern blot analysis with human clusterin cDNA probe.
[View Larger Version of this Image (40K GIF file)]

To determine whether the induction of clusterin mRNA by TGFbeta is at the transcriptional level, we performed transient transfection assays in these different cell lines with a luciferase reporter gene (pRAL) containing the 1.3-kilobase 5'-regulatory region of rat clusterin gene (Fig. 2B). Following transfection, cells were treated with 5 ng/ml TGFbeta for 16 or 20 h. The data (Fig. 2A and Fig. 4) show that TGFbeta induces promoter transactivation with a 2.5-6-fold elevation in luciferase activity in the five cell types analyzed. In transient transfection assays of CCL64 cells, we used this same reporter construct lacking the TATA box in the regulatory region as a negative control (Fig. 2A). This construct failed to induce luciferase activity in response to TGFbeta . The results provide supportive evidence that TGFbeta induces clusterin gene expression, at least in part, at the transcriptional level.


Fig. 4. Mutational analysis of rat clusterin promoter region. The sequence of the AP-1-binding site is shown at the top of the figure. A thymidine in the wild type AP-1-binding site of full-length promoter region was mutated to guanine as indicated by the underlined letter. The wild type and mutant promoter/reporter constructs were transfected into different cells. Luciferase activity of the promoter-reporter construct was measured and normalized by beta -galactosidase activity of SV40 beta -galactosidase plasmid (CCL64 cells) or renilla luciferase activity of pRL-CMV plasmid (other cells). Duplicate transfections were performed for each assay.
[View Larger Version of this Image (28K GIF file)]

Deletional Analysis of a Rat Clusterin Gene 5'-Promoter Region

To analyze the TGFbeta -responsive cis-element(s) of the clusterin promoter, we constructed a series of 5'-deletions of the promoter region of rat clusterin gene. Since the 1.3-kilobase promoter region contains Sp1, AP-2, and AP-1 consensus sites, we decided to make deletions containing different combinations of these conventional binding sites as the first step in our promoter analysis (Figs. 2 and 3). The pRAL-M/Nsi deletion with 586 base pairs truncated from the 5'-promoter region, which still retains all three binding sites, is able to induce TGFbeta transactivation. Two other deletions, pRAL-N/A and pRAL-p2p4, which lack Sp1 and both Sp1 and AP-2 sites, respectively, still show TGFbeta induction of promoter transactivation similar to the full-length promoter/reporter construct. This suggests that Sp1 and AP-2 are not necessary for clusterin transactivation by TGFbeta . However, deletions pRAL-E/E, pRAL-p1p2, and pRAL-AP(-), which remove the AP-1-binding site in the promoter region, abolished TGFbeta -induced promoter transactivation (Fig. 3). The data indicate that the AP-1-binding site in the promoter region is essential for TGFbeta -mediated regulation of clusterin gene expression.


Fig. 3. Deletional analyses of rat clusterin promoter region in transient transfection assays of CCL64 cells. Full-length and deletions of rat clusterin promoter reporter plasmids were transfected into CCL64 cells as described under "Materials and Methods." TGFbeta -induced luciferase activity was measured as relative light units and normalized by beta -glactosidase activity of co-transfected SV40 beta -galactosidase reporter plasmid (Promega). Induction fold was calculated by comparing normalized luciferase activity of TGFbeta -treated cells and untreated control. In each assay, duplicate transfections were performed. These results are from representative experiments. Consensus binding sites are labeled and designated by filled ovals.
[View Larger Version of this Image (31K GIF file)]

The AP-1 Site Is Required for TGFbeta -mediated Induction of Clusterin Gene Transcription

While the deletional analyses revealed that the AP-1-binding site in the clusterin promoter region is important for TGFbeta -mediated induction of clusterin gene expression, we needed to determine whether the AP-1 site is the exclusive element in the clusterin promoter responsible for TGFbeta -mediated gene regulation. To test this, we created a single base mutation within the AP-1-binding site of the promoter region. The wild-type AP-1-binding site is 5'-TGAGTCA-3', while in the mutant construct, the thymidine was replaced by guanine to form an AP-1 mutant, 5'-TGAGGCA-3' termed pT2G (the mutated base is underlined) (Fig. 4). The mutated promoter/luciferase construct, pT2G, contains a single site mutation in the 1.3-kilobase pair rat promoter region. Transfection assays in the various cell types with the wild-type vector show induction of luciferase activity by TGFbeta ; however, the mutated AP-1 promoter/reporter construct fails to show TGFbeta -induced transcriptional activation (Fig. 4).

Transcription Factor Decoy Experiments in CCL64 Cells

We next wished to investigate whether the AP-1 site of the promoter region is specifically responsible for TGFbeta -mediated induction of endogenous clusterin expression in CCL64 cells. To address this question, we designed a 23-mer oligonucleotide containing either the wild-type (AP-1) or mutated (T2G) AP-1-binding site (Fig. 5C). These 23-mer oligonucleotides were transfected into CCL64 cells and used as transcriptional factor decoys in experiments analyzing TGFbeta -mediated regulation of clusterin mRNA levels (Fig. 5A) and promoter transactivation (Fig. 5B). As shown in Fig. 5A, introduction of the wild-type AP-1 oligonucleotide into CCL64 cells dramatically reduced clusterin mRNA level upon TGFbeta stimulation, while the T2G mutated AP-1 oligonucleotide had no effect. In addition, when the AP-1 or T2G oligonucleotides are transiently co-transfected in excess (100:1 nmol) with the full-length pRAL reporter construct (Fig. 5B), only the wild-type AP-1 inhibits TGFbeta -induced luciferase activity. These experiments indicate that TGFbeta -mediated induction of endogenous clusterin also involves the AP-1-binding site.


Fig. 5. Decoy experiments of transcription factors with oligonucleotides containing either a wild-type or mutant AP-1-binding site. A, effect of AP-1 or T2G mutant oligonucleotides on clusterin mRNA production. CCL64 cells (80% confluent) were transfected with 23-mer oligonucleotides containing the AP-1 consensus binding site or a T to G single site AP-1 mutant (T2G), respectively, and treated with TGFbeta for 10 h. Cells were subjected to RNA extraction and Northern hybridization. B, effect of co-transfection of the oligonucleotides on pRAL transgene luciferase activity. AP-1 or T2G-mutant 23-mer oligonucleotides (0.7 mg) were co-transfected along with pRAL and SV40 beta -galactosidase into CCL64 cells. The promoter driven luciferase activity was normalized to beta -glactosidase activity of the SV40 beta -galactosidase plasmid, and the induction fold was calculated as described in the legend to Fig. 3. C, sequences of the 23-mer oligonucleotides containing either an AP-1-binding site (AP-1) or a T to G mutated AP-1 site (T2G). The position of the oligonucleotide in the promoter region is also shown in the figure. The bold faced sequence represents the consensus AP-1-binding site and the underlined indicates the base that was mutated.
[View Larger Version of this Image (30K GIF file)]

Protein Kinase C Is Involved in Mediating TGFbeta -induced Clusterin Gene Expression

Previous research has suggested that several protein kinases, including protein kinase C (PKC), may participate in mediating TGFbeta signaling although their functions and substrates remain to be elucidated (17). We were interested in investigating if the PKC signaling pathway might be involved in mediating TGFbeta -mediated regulation of clusterin gene expression. To address this question, we used two specific pharmacological inhibitors of PKC, namely GF109203X and calphostin C (48, 49), to block TGFbeta -mediated regulation of clusterin gene expression. As shown in Fig. 6A, pretreatment of CCL64 cells with a specific PKC inhibitor, GF109203X (48), blocked the ability of TGFbeta to induce clusterin gene expression in a dose-dependent manner. Another specific PKC inhibitor, calphostin C (49), at concentrations of 50 and 100 nM, was also effective in inhibiting TGFbeta -induced clusterin gene expression as determined by Northern blot analyses (Fig. 6B) and promoter driven luciferase activity in CCL64 cells (Fig. 6C). Calphostin C at 100 nM was also effective in inhibiting TGFbeta -induced promoter activity in HeLa, 3TP, 10T1/2, and BAEC cells (data not shown). Down-regulation of PKC activity by treatment of the cells with 200 ng/ml phorbol myristate acetate (PMA) for 20 h inhibited TGFbeta -induced clusterin mRNA synthesis (data not shown). However, stimulation of PKC in CCL64 cells with 10-100 ng/ml PMA for 0.5-10 h had no effect on clusterin mRNA levels with or without TGFbeta stimulation (data not shown).


Fig. 6. Effect of protein kinase C inhibitors on induction of clusterin gene expression by TGFbeta . A, GF109236X inhibits TGFbeta -induced clusterin mRNA levels in CCL64 cells. Cells were pretreated with 5, 15, and 25 mM GF109236X for 15 min (61) and TGFbeta was added for 12 h prior to the isolation of total RNA and Northern blot analysis. B, effect of calphostin C on TGFbeta -induced clusterin mRNA. CCL64 cells (80% confluent) were pretreated with 100 nM calphostin C for 15 min under room lights followed by stimulation with TGFbeta (5 ng/ml) for the indicated times prior to RNA extraction and Northern hybridization. C, effect of calphostin C pretreatment on clusterin promoter transcriptional activity induced by TGFbeta . After transfection of CCL64 cells with pRAL and SV40 beta -gal, calphostin C was added to the medium at final concentrations of 50 and 100 nM and incubated for 15 min under room lights. Cells were stimulated with TGFbeta (5 ng/ml) for 16 h prior to isolation of cell extracts and measurement of luciferase activity.
[View Larger Version of this Image (38K GIF file)]


DISCUSSION

Clusterin is a multifunctional protein that has been implicated in homeostatic control of lipoprotein metabolism, tissue repair and remodeling, sperm maturation, inhibition of complement mediated cell lysis, and epithelial cell differentiation (30). Expression of clusterin is well regulated during development, cell differentiation, and tissue remodeling, and can be modulated by cytokines, such as TGFbeta (31, 50, 51). Our previous studies have shown that TGFbeta enhances clusterin protein synthesis and RNA levels, and induces the translocation of a cytosolic form of clusterin to the nucleus in CCL64 cells (11). These effects of TGFbeta on clusterin led us to investigate the mechanisms of regulation of clusterin gene expression by TGFbeta . Our data demonstrate that TGFbeta rapidly induces clusterin mRNA levels in a variety of cell lines, including epithelial (CCL64 and HeLa), fibroblast (10T1/2 and 3TP), and BAEC. The induction of clusterin by TGFbeta in mink lung epithelial cells (CCL64) occurs in both rapidly growing, asynchronous cells and in serum-starved G0-arrested cells. This suggests that this induction is not cell cycle dependent since it occurs not only during quiescence but also throughout the cycle. These results also suggest that the induction of clusterin is not secondary to TGFbeta -induced growth arrest because TGFbeta is capable of inducing clusterin in an already G0-arrested cell population, as well in 3TP cells which are not growth arrested by TGFbeta (44). Clusterin mRNA can be induced as early as 30 min after TGFbeta stimulation and remains elevated for at least 24 h in the presence of TGFbeta . This induced expression pattern of clusterin mRNA is similar to that observed with other stimuli where mRNA levels peak within several hours and remain elevated for over 24 h following stimulation (31, 50).

There is over 80% similarity within the first 150 base pairs of the 5'-upstream regulatory region between the human and rat clusterin genes (40). Two conventional cis-elements, Sp1 and AP-1, have been found in the regulatory region of clusterin genes from human, rat, quail, and mouse (39, 40). Several TGFbeta -inhibitory elements have also been identified in the first intron of the rat clusterin gene and in the upstream regulatory region of the avian clusterin gene (38, 40, 41). These cis-elements have been implicated in the regulation of clusterin gene expression by various stimuli (37-41). For example, the T64 gene of quail embryo fibroblasts, corresponding to clusterin in mammals, contains an AP-1-binding site located at position -25 to -19 of the single transcriptional start site. Promoter transactivation of the T64 gene has been shown to be significantly induced by an active v-src oncoprotein, and the v-src response requires the AP-1 site and a purine-rich element (39). There is, however, no evidence to indicate that these cis-elements in the promoter region of clusterin genes regulate TGFbeta induction.

In the present study, a 1.3-kilobase rat clusterin promoter region has been used for identifying cis-elements mediating TGFbeta signaling. This promoter contains AP-1, AP-2, and Sp1 consensus binding sites. Our deletional analyses demonstrate that the AP-2 and Sp1 consensus sites, located at position -124 and -372 from the transcriptional start site, respectively, are not involved in promoter transactivation by TGFbeta . However, removal of the AP-1 consensus site, located at position -73 to -79 relative to the transcription start site, abates TGFbeta induction of promoter transactivation. The data indicate that TGFbeta modulates clusterin gene expression via an AP-1-binding site, and that this AP-1 site is required and sufficient for promoter transactivation by TGFbeta . The importance of the AP-1 site in the induction of the clusterin gene by TGFbeta is confirmed by our mutagenesis experiments of the AP-1 site in the clusterin promoter region. A single base pair mutation, T to G in the AP-1-binding site, abolished TGFbeta -promoter transactivation, indicating that the AP-1 site is necessary for TGFbeta -induced clusterin expression. Decoy experiments with 23-mer AP-1 oligonucleotides also demonstrate that the AP-1 site is required for TGFbeta induction of the endogenous clusterin gene. Transfection of the wild-type AP-1 oligonucleotide into CCL64 cells markedly decreases TGFbeta induction of clusterin mRNA levels and promoter transactivation. Transfection of the T to G mutated AP-1 failed to serve as a decoy of the endogenous AP-1 site in the clusterin gene and had no effect on the ability of TGFbeta to induce endogenous clusterin gene expression. The data indicate that TGFbeta regulation of endogenous clusterin expression in CCL64 cells is also mediated via the AP-1-binding site and its cognate transcription factors.

In addition to clusterin, a large number of TGFbeta responsive genes, such as JE/MCP-1(25), c-jun (7, 51), plasminogen activator inhibitor type-1 (8), and alpha 2(I)-collagen (62), contain AP-1-binding sites in their 5'-regulatory region. Expression of these genes can be modulated by TGFbeta and requires involvement of the AP-1-binding site and its cognate transcription factor. The collagenase gene has also been shown to be regulated by TGFbeta in a cell type specific manner through an AP-1 site. In fibroblast cells, for example, TGFbeta inhibits collagenase gene expression through an AP-1 site presumably via an up-regulation of junB (63). Overexpression of junB mimics the inhibitory effects of TGFbeta on collagenase expression. In contrast, TGFbeta -induced collagenase expression in keratinocytes is preceded by a transient elevation of c-jun expression, which is suggested to be a ubiquitous inducer of collagenase gene expression (63). These results demonstrate that cell-specific induction of different AP-1 family members, with opposite trans-activating properties, are responsible for the differences observed in TGFbeta regulation of collagenase gene expression. Taken together, these data establish that AP-1 is a mediator of TGFbeta -induced gene transcription. However, the mechanism through which TGFbeta modulates AP-1 activity and the individual AP-1 family members which are induced or suppressed by TGFbeta , in a cell-type and gene-specific fashion, remain to be determined.

We postulated that since the promoter region of the rat clusterin gene contains an AP-1-binding site, which is required for TGFbeta induction, that PKC activity might mediate TGFbeta induction. It is well established that activation of PKC by 12-O-tetradecanoylphorbol-13-acetate results in increased synthesis of c-Fos and c-Jun proteins which are required for the formation of the AP-1 transcriptional complex (AP-1) (53, 54). Upon activation and translocation to the nucleus, the AP-1 protein binds to the 12-O-tetradecanoylphorbol-13-acetate responsive elements mediating activation of 12-O-tetradecanoylphorbol-13-acetate inducible genes (7, 53, 54). The 12-O-tetradecanoylphorbol-13-acetate responsive element has been identified as an AP-1-binding site, and the AP-1 site as well as its cognate transcription factors are directly related to phorbol ester, a PKC regulatory reagent (51, 55-57). It has been postulated that activated PKC leads to dephosphorylation of c-Jun protein at sites which negatively regulate DNA binding activity and thereby augments AP-1 activity (64). PKC has also been implicated in TGFbeta signaling. In A549 human lung carcinoma cells, TGFbeta has been shown to induce promoter transactivation of 3TP-Lux, a TGFbeta -inducible artificial promoter construct which contains 3 12-O-tetradecanoylphorbol-13-acetate responsive elements (17). TGFbeta induction of this promoter construct can be inhibited by prior treatment of the cells with PKC inhibitors and down-regulation of PKC with PMA (17). In the present study we demonstrate that inhibition of PKC activity by two distinct types of PKC inhibitors blocked TGFbeta -induced clusterin mRNA levels and promoter transactivation, thus providing further support for the role of AP-1 in TGFbeta regulation of clusterin gene expression. Stimulation of PKC activity by treatment of the cells with PMA, however, had no effect on clusterin mRNA levels or TGFbeta -induced clusterin mRNA levels. These results suggest that activation of PKC alone is not sufficient for regulating clusterin gene expression but that PKC activity is necessary for TGFbeta -induced clusterin gene expression. These data are in agreement with the observation that PMA treatment does not coordinate phosphorylation of nuclear proteins in CCL64 cells, whereas TGFbeta stimulates nuclear protein phosphorylation (20). These results are also similar to those observed in activated T cells where full activation of AP-1 requires both the calcium- and PKC-dependent pathways (60). Perhaps TGFbeta -inducible clusterin gene expression requires multiple signaling pathways to fully activate AP-1 and that inhibiting one of these signaling cascades (i.e. PKC) results in insufficient activation of AP-1 to induce proper transcriptional regulation.

Recent studies in TGFbeta signaling indicate that binding of TGFbeta to its dimeric receptor complex, composed of the type I and type II receptors, initiates a serine/threonine phosphorylation cascade that involves the Smad proteins. These signaling molecules are phosphorylated on serine and threonine residues by the type I TGFbeta receptor and once activated translocate to the nucleus where they are postulated to interact with other Smad proteins and/or transcription factors to initiate target gene expression (65). Future research will be directed at determining how these Smad proteins interact with members of the AP-1 family to regulate gene transcription and how PKC regulates this interaction.


FOOTNOTES

*   This work was supported in part by National Institutes of Health Grant CA55536 (to P. H. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Established Investigator of the American Heart Association. To whom correspondence and reprint requests should be addressed: Dept. of Cell Biology NC-1, the Cleveland Clinic Foundation, Lerner Research Institute, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-445-9750; Fax: 216-445-7855.
1   The abbreviations used are: TGFbeta , transforming growth factor beta ; CCL64 cells, mink lung epithelial cells; BAEC, bovine aortic endothelial cell; PMA, phorbol myristate acetate; clusterin, also known as apolipoprotein J; CDTA, 1,2-diaminocydoheane-N,N,N',N'-tetraacetic acid; AP-1, activator protein 1; DMEM, Dulbecco's modified Eagle's medium; PKC, protein kinase C.

ACKNOWLEDGEMENTS

We thank Drs. Tom Brown and Barbara Hocevar for helpful discussions and critical review of the manuscript. We also thank Dr. Martin Tenniswood for the rat clusterin promoter construct and Dr. Mark Hamilton for 10T1/2 cells.


REFERENCES

  1. Massague, J. (1987) Cell 49, 437-438 [CrossRef][Medline] [Order article via Infotrieve]
  2. Moses, H. L., Keski-Oja, J., Lyons, R. M., Sipes, N. J., Bascom, C. C., and Coffey, R. J., Jr. (1989) Advances in Growth Hormone and Growth Factor Research, pp. 191-199, Pythagovation Press, Rome
  3. Baird, A., and Durkin, T. (1986) Biochem. Biophys. Res. Commun. 138, 476-482 [CrossRef][Medline] [Order article via Infotrieve]
  4. Miller, D. A., Lee, A., Pelton, R. W., Chen, E. Y., Moses, H. L., and Derynck, R. (1989) Mol. Endocrinol. 3, 1108-1114 [Abstract/Free Full Text]
  5. Massague, J. (1990) Annu. Rev. Cell Biol. 6, 597-641 [CrossRef]
  6. Miyazono, K., Ten, Dijke, P., Ichijo, H., and Heldin, C. H. (1994) Adv. Immunol. 55, 181-220 [Medline] [Order article via Infotrieve]
  7. de Groot, R. P., and Kruijer, W. (1990) Biochem. Biophys. Res. Commun. 168, 1074-1081 [CrossRef][Medline] [Order article via Infotrieve]
  8. Keeton, M. R., Curriden, S. A., van Zonneveld, A.-J., and Loskutoff, D. J. (1991) J. Biol. Chem. 266, 23048-23052 [Abstract/Free Full Text]
  9. Li, L., Hu, J.-S., and Olson, E. N. (1989) J. Biol. Chem. 265, 1556-1562 [Abstract/Free Full Text]
  10. Van Obberghen-Schilling, E., Roche, N. S., Flanders, K. C., Sporn, M. B., and Roberts, A. B. (1988) J. Biol. Chem. 263, 7741-7746 [Abstract/Free Full Text]
  11. Reddy, K. B., Jin, G., Karode, M. C., Harmony, J. A., and Howe, P. H. (1996) Biochemistry 35, 6157-6163 [CrossRef][Medline] [Order article via Infotrieve]
  12. Ebner, R., Chen, R. H., Shum, L., Lawler, S., Zioncheck, T. F., Lee, A., Lopez, A. R., and Derynck, R. (1993) Science 260, 1344-1348 [Abstract/Free Full Text]
  13. Brandes, M. E., Mai, U. E., Ohura, K., and Wahl, S. M. (1991) J. Immunol. 147, 1600-1606 [Abstract]
  14. Rodriguez, C., Chen, F., Weinberg, R. A., and Lodish, H. F. (1995) J. Biol. Chem. 270, 15919-15922 [Abstract/Free Full Text]
  15. Massague, J. (1996) Cell 85, 947-950 [CrossRef][Medline] [Order article via Infotrieve]
  16. Nakao, A., Roijer, E., Imamura, T., Souchelnytskyi, S., Stenman, G., Heldin, C.-H., and ten Dijke, P. (1997) J. Biol. Chem. 272, 2896-2900 [Abstract/Free Full Text]
  17. Halstead, J., Kemp, K., and Ignotz, R. A. (1995) J. Biol. Chem. 270, 13600-13603 [Abstract/Free Full Text]
  18. Kramer, I. M., Koornneef, I., de Laat, S. W., and van den Eijnden-van Raaij, A. J. (1991) EMBO J. 10, 1083-1089 [Medline] [Order article via Infotrieve]
  19. Atfi, A., Lepage, K., Allard, P., Chadpdelaine, A., and Chevalier, S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 12110-12114 [Abstract/Free Full Text]
  20. Ohtsuki, M., and Massague, J. (1992) Mol. Cell. Biol. 12, 261-265 [Abstract/Free Full Text]
  21. Shibuya, H., Yamaguchi, K., Shirakabe, K., Tonegawa, A., Gotoh, Y., Ueno, N., Irie, K., Nishida, E., and Matsumoto, K. (1996) Science 272, 1179-1182 [Abstract]
  22. Wang, T., Danielson, P. D., Li, B., Shah, P. C., Kim, S. D., and Donahoe, P. K. (1996) Science 271, 1120-1122 [Abstract]
  23. Westerhausen, D. R., Jr., Hopkins, W. E., and Billadello, J. J. (1991) J. Biol. Chem. 266, 1092-1100 [Abstract/Free Full Text]
  24. Kerr, L. D., Miller, D. B., and Matrisian, L. M. (1990) Cell 61, 267-278 [CrossRef][Medline] [Order article via Infotrieve]
  25. Takeshita, A., Chen, Y., Watanabe, A., Kitano, S., and Hanazawa, S. (1995) J. Immuol. 155, 419-426 [Abstract]
  26. Kim, S. J., Angel, P., Lafyatis, R., Hattori, K., Kim, K. Y., Sporn, M. B., Karin, M., and Roberts, A. B. (1990) Mol. Cell Biol. 10, 1492-1497 [Abstract/Free Full Text]
  27. Inagaki, Y., Truter, S., and Ramirez, F. (1994) J. Biol. Chem. 269, 14828-14834 [Abstract/Free Full Text]
  28. Datto, M. B., Yu, Y., and Wang, X.-F. (1995) J. Biol. Chem. 270, 28623-28628 [Abstract/Free Full Text]
  29. Rossi, P., Karsenty, G., Roberts, A. B., Roche, N. S., Sporn, M. B., and de Crombrugghe, B. (1988) Cell 52, 405-414 [CrossRef][Medline] [Order article via Infotrieve]
  30. Blaschuk, O., Burdzy, K., and Fritz, I. B. (1983) J. Biol. Chem. 258, 7714-7720 [Abstract/Free Full Text]
  31. Jenne, D. E., and Tschopp, J. (1992) Trends Biochem. Sci. 17, 154-159 [CrossRef][Medline] [Order article via Infotrieve]
  32. Wong, P., Taillefer, D., Lakins, J., Pineault, J., Chader, G., and Tenniswood, M. (1994) Eur. J. Biochem. 221, 917-925 [Medline] [Order article via Infotrieve]
  33. Burkey, B. F., de Silva, H. V., and Harmony, J. A. (1991) J. Lipid Res. 32, 1039-4108 [Abstract]
  34. Bettuzzi, S., Troiano, L., Davalli, P., Tropea, F., Ingletti, M. C., Grassilli, E., Monti, D., Corti, A., and Franceschi, C. (1991) Biochem. Biophys. Res. Commun. 175, 810-815 [CrossRef][Medline] [Order article via Infotrieve]
  35. Thomas-Salgar, S., and Millis, A. J. T. (1994) J. Biol. Chem. 269, 17879-17885 [Abstract/Free Full Text]
  36. Brown, T. L., Moulton, B. C., Witte, D. P., Swertfeger, D. K., and Harmony, J. A. (1996) Biol. Reprod. 55, 740-747 [Abstract]
  37. Brown, T. L., Moulton, B. C., Baker, V. V., Mira, J., and Harmony, J. A. (1995) Biol. Reprod. 52, 1038-1049 [Abstract]
  38. Wong, P., Pineault, J., Lakins, J., Taillefer, D., Leger, J., Wang, C., and Tenniswood, M. (1993) J. Biol. Chem. 268, 5021-5031 [Abstract/Free Full Text]
  39. Herault, Y., Chatelain, G., Brun, G., and Michel, D. (1992) Nucleic Acids Res. 20, 6377-6383 [Abstract/Free Full Text]
  40. Michel, D., Chatelain, G., Herault, Y., and Brun, G. (1995) Eur. J. Biochem. 229, 215-223 [Medline] [Order article via Infotrieve]
  41. Rosemblit, N., and Chen, C. L. (1994) J. Mol. Endocrinol. 13, 69-76 [Abstract/Free Full Text]
  42. Morgan, T. E., Laping, N. J., Rorovsky, I., Oda, T., Hogan, T. H., Finch, C. E., and Pasinetti, G. M. (1995) J. Neuroimmunol. 58, 101-110 [CrossRef][Medline] [Order article via Infotrieve]
  43. Reddy, K. B, Karode, M. C., Harmony, J. A., and Howe, P. H. (1996) Biochemistry 35, 309-314 [CrossRef][Medline] [Order article via Infotrieve]
  44. Hocevar, B., and Howe, P. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7655-7660 [Abstract/Free Full Text]
  45. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159 [Medline] [Order article via Infotrieve]
  46. Deng, W. P., and Nickoloff, J. A. (1992) Anal. Biochem. 200, 81-88 [CrossRef][Medline] [Order article via Infotrieve]
  47. Campbell, M. J. (1995) Biotechniques 18, 1027-1032 [Medline] [Order article via Infotrieve]
  48. Muid, R. E., Dale, M. M., Davis, P. D., Elliot, L. H., Hill, C. H., Kumar, H., Lawton, G., Twomey, B. M., Wadsworth, J., Wilkinson, S. E., and Nixon, J. S. (1991) FEBS Lett. 293, 169-72 [CrossRef][Medline] [Order article via Infotrieve]
  49. Bruns, R. F., Miller, F. D., Merriman, R. L., Howbert, J. J., Heath, W. F., Kobayashi, E., Takahashi, I., Tamaoki, T., and Nakano, H. (1991) Biochem. Biophys. Res. Commun. 176, 288-293 [CrossRef][Medline] [Order article via Infotrieve]
  50. Hardardottir, I., Kunitake, S. T., Moser, A. H., Doerrler, W. T., Rapp, J. H., Grunfeld, C., and Feingold, K. R. (1994) J. Clin. Invest. 94, 1304-1309
  51. Zwain, I. H., Grima, J., and Cheng, C. Y. (1994) Mol. Cell Neurosci. 5, 229-237 [CrossRef][Medline] [Order article via Infotrieve]
  52. Wong, P., Kutty, R. K., Darrow, R. M., and Organsciak, D. T. (1994) Biochem. Cell Biol. 72, 449-503
  53. Hattori, K., Angel, P., LeBeau, M. M., and Karin, M. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 9148-9152 [Abstract/Free Full Text]
  54. Mitchell, P. J., and Tjian, R. (1989) Science 245, 371-378 [Abstract/Free Full Text]
  55. Verma, I. M., and Sassone-Corsi, P. (1987) Cell 51, 513-514 [CrossRef][Medline] [Order article via Infotrieve]
  56. Angel, P., Hattori, K., Smeal, T., and Karin, M. (1988) Cell 55, 875-885 [CrossRef][Medline] [Order article via Infotrieve]
  57. Lee, W., Michell, P., and Tjian, R. (1987) Cell 49, 741-752 [CrossRef][Medline] [Order article via Infotrieve]
  58. Deleted in proofDeleted in proof
  59. Deleted in proofDeleted in proof
  60. Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M., and Ben-Nerich, Y. (1994) Cell 77, 727-736 [CrossRef][Medline] [Order article via Infotrieve]
  61. Li, Q., and Cathcart, M. K. (1994) J. Biol. Chem. 269, 17508-17515 [Abstract/Free Full Text]
  62. Chung, K.-Y., Agarwal, A., Uitto, J., and Mauviel, A. (1996) J. Biol. Chem. 271, 3272-3278 [Abstract/Free Full Text]
  63. Mauviel, A., Chung, K.-Y., Agarwal, A., Tamai, T., and Uitto, J. (1996) J. Biol. Chem. 271, 10917-10923 [Abstract/Free Full Text]
  64. Boyle, W. J., Smeal, T., Defize, J. H. K., Angel, P., Woodgett, J. R., Karin, M., and Hunter, T. (1991) Cell 64, 573-584 [CrossRef][Medline] [Order article via Infotrieve]
  65. Massague, J., Hata, A., and Liu, F. (1997) Trends Cell Biol. 7, 187-192

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
IOVSHome page
B. Ovodenko, A. Rostagno, T. A. Neubert, V. Shetty, S. Thomas, A. Yang, J. Liebmann, J. Ghiso, and R. Ritch
Proteomic Analysis of Exfoliation Deposits
Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1447 - 1457.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
A. Ishii, Y. Sakai, and A. Nakamura
Molecular Pathological Evaluation of Clusterin in a Rat Model of Unilateral Ureteral Obstruction as a Possible Biomarker of Nephrotoxicity
Toxicol Pathol, April 1, 2007; 35(3): 376 - 382.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
S. M. Fennewald, E. P. Scott, L. Zhang, X. Yang, J. F. Aronson, D. G. Gorenstein, B. A. Luxon, R. E. Shope, D. W. C. Beasley, A. D. T. Barrett, et al.
Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections
J. Gen. Virol., March 1, 2007; 88(3): 981 - 990.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. R. Cochrane, Z. Wang, M. Muramaki, M. E. Gleave, and C. C. Nelson
Differential Regulation of Clusterin and Its Isoforms by Androgens in Prostate Cells
J. Biol. Chem., January 26, 2007; 282(4): 2278 - 2287.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
L. O'Driscoll, P. Gammell, E. McKiernan, E. Ryan, P. B. Jeppesen, S. Rani, and M. Clynes
Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells
J. Endocrinol., December 1, 2006; 191(3): 665 - 676.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. Zenkel, F. E. Kruse, A. G. Junemann, G. O. H. Naumann, and U. Schlotzer-Schrehardt
Clusterin Deficiency in Eyes with Pseudoexfoliation Syndrome May Be Implicated in the Aggregation and Deposition of Pseudoexfoliative Material
Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1982 - 1990.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Bayon, M. A. Ortiz, F. J. Lopez-Hernandez, P. H. Howe, and F. J. Piedrafita
The Retinoid Antagonist MX781 Induces Clusterin Expression in Prostate Cancer Cells via Heat Shock Factor-1 and Activator Protein-1 Transcription Factors
Cancer Res., August 15, 2004; 64(16): 5905 - 5912.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
B.-H. Min, B.-M. Kim, S.-H. Lee, S.-W. Kang, M. Bendayan, and I.-S. Park
Clusterin Expression in the Early Process of Pancreas Regeneration in the Pancreatectomized Rat
J. Histochem. Cytochem., October 1, 2003; 51(10): 1355 - 1365.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-K. Leivonen, A. Chantry, L. Hakkinen, J. Han, and V.-M. Kahari
Smad3 Mediates Transforming Growth Factor-beta -induced Collagenase-3 (Matrix Metalloproteinase-13) Expression in Human Gingival Fibroblasts. EVIDENCE FOR CROSS-TALK BETWEEN Smad3 AND p38 SIGNALING PATHWAYS
J. Biol. Chem., November 22, 2002; 277(48): 46338 - 46346.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K. H. Yoo, B. A. Thornhill, and R. L. Chevalier
Angiotensin stimulates TGF-beta 1 and clusterin in the hydronephrotic neonatal rat kidney
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2000; 278(3): R640 - R645.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Urbich, M. Fritzenwanger, A. M. Zeiher, and S. Dimmeler
Laminar Shear Stress Upregulates the Complement-Inhibitory Protein Clusterin : A Novel Potent Defense Mechanism Against Complement-Induced Endothelial Cell Activation
Circulation, February 1, 2000; 101(4): 352 - 355.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. Eickelberg, A. Pansky, R. Mussmann, M. Bihl, M. Tamm, P. Hildebrand, A. P. Perruchoud, and M. Roth
Transforming Growth Factor-beta 1 Induces Interleukin-6 Expression via Activating Protein-1 Consisting of JunD Homodimers in Primary Human Lung Fibroblasts
J. Biol. Chem., April 30, 1999; 274(18): 12933 - 12938.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. T. Liberati, M. B. Datto, J. P. Frederick, X. Shen, C. Wong, E. M. Rougier-Chapman, and X.-F. Wang
Smads bind directly to the Jun family of AP-1 transcription factors
PNAS, April 27, 1999; 96(9): 4844 - 4849.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Virolle, M.-N. Monthouel, Z. Djabari, J.-P. Ortonne, G. Meneguzzi, and D. Aberdam
Three Activator Protein-1-binding Sites Bound by the Fra-2·JunD Complex Cooperate for the Regulation of Murine Laminin alpha 3A (lama3A) Promoter Activity by Transforming Growth Factor-beta
J. Biol. Chem., July 10, 1998; 273(28): 17318 - 17325.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Qing, Y. Zhang, and R. Derynck
Structural and Functional Characterization of the Transforming Growth Factor-beta -induced Smad3/c-Jun Transcriptional Cooperativity
J. Biol. Chem., December 1, 2000; 275(49): 38802 - 38812.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
W. Xu, K. Angelis, D. Danielpour, M. M. Haddad, O. Bischof, J. Campisi, E. Stavnezer, and E. E. Medrano
Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor
PNAS, May 23, 2000; 97(11): 5924 - 5929.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, G.
Right arrow Articles by Howe, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jin, G.
Right arrow Articles by Howe, P. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement